ALLMedicine™ Breast Cancer Treatment Center

Feb 23rd, 2021 - To review the settings and outcomes of high-intensity interval training (HIIT) interventions for breast cancer survivors, and to explore the feasibility of prescribing exercise for breast cancer survivors. A systematic search of electronic databas...

Feb 23rd, 2021 - Polo-like kinase 1 (PLK1) is a protein kinase that is overexpressed in breast cancer and may represent an attractive target for breast cancer treatment. However, few studies have investigated the relationship between PLK1 and radiosensitivity in b...

Feb 22nd, 2021 - Purpose: Healthy lifestyle interventions after breast cancer treatment have generally been studied in terms of weight-loss outcomes, which leaves a gap in our understanding of the phenomenological experience of such programs. Our knowledge of how ...

Feb 20th, 2021 - Nanoparticle albumin-bound paclitaxel (nab-PTX) has exhibited clinical efficacy in breast cancer treatment, but toxicities can be yielded more at the same time. We did this meta-analysis aiming to unambiguously compare nab-PTX with conventional so...

Feb 19th, 2021 - Angiosarcoma of the breast is rare and aggressive. It can occur as a de novo tumor or secondary to breast cancer treatment. The purpose of this study is to analyze differences between patients with primary and secondary angiosarcoma of the breast ...

Oct 3rd, 2019 - Breast cancer is the most common noncutaneous cancer in U.S. women, with an estimated 62,930 cases of in situ disease and 268,600 cases of invasive disease in 2019.[1] Thus, fewer than one of six women diagnosed with breast cancer die of the disea...

Feb 13th, 2019 - Substantial progress has been made over the past 50 years in the evaluation and treatment of patients with breast cancer, leading to a nearly 40% decrease in mortality from this disease and associated reductions in complications of treatment. This...

Feb 13th, 2019 - Patients who have residual invasive breast cancer after receiving neoadjuvant chemotherapy plus human epidermal growth factor receptor 2 (HER2)–targeted therapy have a worse prognosis than those who have no residual cancer. Trastuzumab emtansine (...

Feb 10th, 2019 - Mammography screening and improved treatments have prevented between 384,000 and 614,500 breast cancer deaths since 1989, according to a study published in Cancer. “Recent reviews of mammography screening have focused media attention on some of th...

Jan 30th, 2019 - This subtype analysis of the BOLERO-2 trial was designed to evaluate outcomes following treatment with everolimus plus exemestane among patients with one of two non-luminal breast cancer subtypes, human epidermal growth factor receptor 2 (HER2)–en...

Feb 23rd, 2021 - To review the settings and outcomes of high-intensity interval training (HIIT) interventions for breast cancer survivors, and to explore the feasibility of prescribing exercise for breast cancer survivors. A systematic search of electronic databas...

Feb 23rd, 2021 - Polo-like kinase 1 (PLK1) is a protein kinase that is overexpressed in breast cancer and may represent an attractive target for breast cancer treatment. However, few studies have investigated the relationship between PLK1 and radiosensitivity in b...

Feb 22nd, 2021 - Purpose: Healthy lifestyle interventions after breast cancer treatment have generally been studied in terms of weight-loss outcomes, which leaves a gap in our understanding of the phenomenological experience of such programs. Our knowledge of how ...

Feb 20th, 2021 - Nanoparticle albumin-bound paclitaxel (nab-PTX) has exhibited clinical efficacy in breast cancer treatment, but toxicities can be yielded more at the same time. We did this meta-analysis aiming to unambiguously compare nab-PTX with conventional so...

Feb 19th, 2021 - Angiosarcoma of the breast is rare and aggressive. It can occur as a de novo tumor or secondary to breast cancer treatment. The purpose of this study is to analyze differences between patients with primary and secondary angiosarcoma of the breast ...

Dec 9th, 2020 - More than one in eight women who undergo mastectomy with reconstruction for breast cancer treatment or prophylaxis become persistent users of controlled substances thereafter, according to a retrospective cohort study reported at the 2020 San Anto...

Nov 22nd, 2020 - The 5-year survival estimates for women with metastatic breast cancer (MBC) hover around 28%, according to the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) data from 2010 to 2016. But closer scrutiny of the evolut...

Nov 15th, 2020 - Pregnancy after treatment for breast cancer with BRCA mutations is safe, with excellent fetal outcomes and no increase in cancer recurrence, say researchers reporting a review of more than 1000 young women with breast cancer, mostly in Europe but ...

Jun 28th, 2020 - The US Food and Drug Administration approved a combination of pertuzumab (Perjeta, Genentech/Roche), trastuzumab (Herceptin, Genentech/Roche) and hyaluronidase (Phesgo, Genentech/Roche) that is administered subcutaneously — rather than intravenous...

Jun 28th, 2020 - The US Food and Drug Administration approved a combination of pertuzumab (Perjeta, Genentech/Roche), trastuzumab (Herceptin, Genentech/Roche) and hyaluronidase (Phesgo, Genentech/Roche) that is administered subcutaneously — rather than intravenous...